Banka BioLoo Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook
- April 14, 2026
- Posted by: Neeraj Pandey
- Category: News
Banka BioLoo (BANKABIOLOO) Q4 FY26 results are scheduled for May 15, 2026, when the company’s board of directors will approve the financial statements for the January-March 2026 quarter. Trading at Rs 88 as of April 2026 — down -41% from its 52-week high of Rs 155 — the stock has been under pressure alongside its peers in the Sanitation / ESG Infrastructure sector. This Q4 results preview covers the confirmed results date, analyst consensus estimates, five key performance factors, five risks to monitor, analyst ratings, and the complete share price outlook.
Banka BioLoo’s Q4 FY26 earnings will be watched for signals on the company’s +20% revenue YoY trajectory, and whether operating metrics are recovering toward normalised levels. This article provides a structured preview based on analyst consensus data and publicly available financial information.
Get free investment predictions on Univest.
Banka BioLoo Q4 Results 2026 Date
The Banka BioLoo Q4 FY26 results date is May 15, 2026. The board of directors will meet to approve the audited consolidated and standalone financial results for the quarter ended March 31, 2026, and the full year FY2025-26.
Here is a broader view of the Q4 FY26 results calendar for reference:
| Company | Results Date | Key Metric |
| TCS | April 9, 2026 (Declared) | FY27 revenue guidance, deal TCV |
| Infosys | April 23, 2026 | CC growth guidance for FY27 |
| Bharat Electronics (BEL) | May 8, 2026 | Order book execution, EBITDA margin |
| Bharat Forge | May 10, 2026 | Global CV + defence execution |
| Banka BioLoo | May 15, 2026 | See estimates below |
Why Q4 FY26 Matters
Q4 (January-March) is the final quarter of FY26, making it the most important earnings event of the year. Beyond the quarterly numbers, investors will receive: full-year FY26 financial summary, management commentary on FY27 business outlook, and the final dividend recommendation for FY26 shareholders.
For Banka BioLoo specifically, Q4 FY26 captures the peak season dynamics of the Sanitation / ESG Infrastructure sector. Management’s commentary on FY27 demand visibility will set the investment narrative for the next 12 months.
Banka BioLoo Q4 FY26 Earnings Estimates
Access premium research on Univest.
Based on publicly available analyst consensus, here are the Q4 FY26 estimates for Banka BioLoo:
| Metric | Q4 FY26 Estimate | Q3 FY26 Actual | Trend |
| Revenue | Rs 42 Cr | Rs 35 Cr | QoQ expected improvement |
| Net Profit (PAT) | Rs 4 Cr | Rs 3 Cr | Normalisation expected |
| Margin | EBITDA 10% | Q3 FY26 margin | QoQ trend |
| Volume / Growth Driver | +20% revenue YoY | Prior quarter | YoY |
| Dividend (Expected) | Rs 0 (no dividend) | FY26 interim dividends | Final dividend |
Screen Banka BioLoo live fundamentals on the Univest Screener.
Download the Univest iOS App or Univest Android App for real-time Q4 result alerts and analyst updates.
5 Key Factors Driving Banka BioLoo Q4 FY26 Performance
1. Government Sanitation Contracts
Banka BioLoo installs bio-toilet systems for Indian Railways, military establishments, and government bodies. Swachh Bharat Mission Phase 2 funding and Indian Railways’ modernisation programme are the primary revenue drivers.
2. Bio-Digester Technology
The company’s proprietary bio-digester technology for portable and permanent toilets positions it in the growing sanitation infrastructure market. Technology differentiation creates competitive moat in specific segments.
3. Rural Sanitation Drive
Rural India’s sanitation infrastructure continues to receive government investment. Banka BioLoo’s low-cost bio-toilet solutions for rural community use are a growing segment.
4. Defence and Military Installations
Defence establishment sanitation contracts provide a stable, high-quality revenue stream with government payment guarantees.
5. ESG Investor Interest
Companies addressing India’s sanitation gap attract ESG-focused investor attention, which can create valuation premiums relative to financial metrics.
5 Risks to Watch in Banka BioLoo Q4 FY26
Risk 1: Government Payment Timelines
Government contract payments can be delayed, creating working capital stress.
Risk 2: Small Scale
At Rs 185 crore market cap, this is a micro-cap company with governance and liquidity risks.
Risk 3: Contract Concentration
Revenue concentrated in few large government contracts creates quarterly lumpiness.
Risk 4: Technology Competition
Larger sanitation infrastructure companies can develop or license similar technologies.
Risk 5: Execution Complexity
Large-scale toilet installation projects require managing supply chains, installation teams, and quality across diverse geographic locations.
Banka BioLoo Share Price and Analyst Ratings
| Parameter | Value |
| CMP (April 2026) | Rs 88 |
| 52-Week High | Rs 155 |
| 52-Week Low | Rs 72 |
| 1-Year Return | -41% |
| Market Capitalisation | Rs 185 Cr |
| Sector | Sanitation / ESG Infrastructure |
| NSE Ticker | BANKABIOLOO |
Analyst ratings and target prices based on publicly available brokerage research:
| Brokerage | Rating | Target Price | Investment Thesis |
| Hem Securities | BUY | Rs 115 | Swachh Bharat spending continues |
| Marwadi Shares | NEUTRAL | Rs 90 | Execution risk at scale |
Conclusion
Banka BioLoo Q4 FY26 will reflect government sanitation contract execution. Revenue above Rs 42 crore with positive EBITDA would be a beat. The Indian Railways and Swachh Bharat Mission pipeline provides multi-year revenue visibility.
Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All financial data and analyst estimates are sourced from publicly available information including NSE/BSE filings and company investor relations pages. Verify all numbers before investing. Consult a SEBI-registered advisor before making investment decisions.
For more Q4 FY26 results previews, visit Univest Blogs.
Frequently Asked Questions
Q: When is Banka BioLoo Q4 results 2026 date?
Banka BioLoo Q4 FY26 results date is May 15, 2026. The board of directors will meet on this date to approve the quarterly and full-year FY26 financial results and consider recommending a final dividend.
Q: What is Banka BioLoo Q4 FY26 revenue estimate?
Analyst consensus estimate for Banka BioLoo Q4 FY26 revenue is Rs 42 Cr. Q3 FY26 actual revenue was Rs 35 Cr. Actual Q4 results may vary based on operating conditions.
Q: What is Banka BioLoo Q4 FY26 PAT estimate?
Analyst consensus estimate for Banka BioLoo Q4 FY26 net profit (PAT) is Rs 4 Cr. Q3 FY26 actual PAT was Rs 3 Cr. Estimates are indicative and not guaranteed.
Q: Will Banka BioLoo declare a dividend in Q4 FY26?
Banka BioLoo is expected to declare Rs 0 (no dividend) for FY26, subject to board approval at the May 15, 2026 board meeting and subsequent shareholder approval at the AGM.
Q: What is Banka BioLoo current share price?
Banka BioLoo is trading at Rs 88 as of April 2026, with a 52-week range of Rs 72 to Rs 155. The 1-year return is -41%.
Q: What were Banka BioLoo Q3 FY26 results?
In Q3 FY26, Banka BioLoo reported revenue of Rs 35 Cr and net profit (PAT) of Rs 3 Cr. The Q4 FY26 results on May 15, 2026 will provide a comparison to assess sequential and year-on-year trends.
Q: When do TCS and Infosys announce Q4 results 2026?
TCS declared Q4 FY26 results on April 9, 2026 (see the Banka BioLoo earnings calendar table above). Infosys is scheduled to declare results on April 23, 2026. Both are covered in detail on Univest Blogs.
Q: Is Banka BioLoo a good investment ahead of Q4 results?
This article does not constitute investment advice. Banka BioLoo trades at Rs 88 with a 52-week range of Rs 72 to Rs 155. Analyst consensus targets and the Q4 FY26 estimates suggest monitoring the results date closely. Consult a SEBI-registered financial advisor for personalised investment guidance.
Recent Article
Balkrishna Industries Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook
Balkrishna Paper Mills Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook
BALAXI PHARMACEUTICALS Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook
Balaji Telefilms Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook
Balaji Amines Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook
